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Recent reports suggest that autoantibodies directed to aberrantly glycosylated mucins, in particular MUC1 and MUC4, are found
in patients with colorectal cancer. There is, however, limited information on the autoantibody levels before clinical diagnosis,
and their utility in cancer screening in the general population. In our study, we have generated O-glycosylated synthetic MUC1
and MUC4 peptides in vitro, to mimic cancer-associated glycoforms, and displayed these on microarrays. The assay’s perform-
ance was tested through an initial screening of serum samples taken from patients at the time of colorectal cancer diagnosis
and healthy controls. Subsequently, the selected biomarkers were evaluated in a blinded nested case–control study using stored
serum samples from among the 50,640 women randomized to the multimodal arm of the UK Collaborative Trial of Ovarian Can-
cer Screening (UKCTOCS), where women gave annual blood samples for several years. Cases were 97 postmenopausal women
who developed colorectal cancer after recruitment and were age-matched to 97 women without any history of cancer. MUC1-STn
and MUC1-Core3 IgG autoantibodies identified cases with 8.2 and 13.4% sensitivity, respectively, at 95% specificity. IgA to
MUC4 glycoforms were unable to discriminate between cases and controls in the UKCTOCS sera. Additional analysis was under-
taken by combining the data of MUC1-STn and MUC1-Core3 with previously generated data on autoantibodies to p53 peptides,
which increased the sensitivity to 32.0% at 95% specificity. These findings suggest that a combination of antibody signatures
may have a role as part of a biomarker panel for the early detection of colorectal cancer.
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Autoantibodies against tumor-associated antigens (TAAs) are
emerging as potent biomarkers for early cancer detection.1,2
However, autoantibodies to single targets do not possess sufﬁ-
cient diagnostic sensitivity and speciﬁcity to be used as screening
tests. It is generally believed that multiplexed assays with several
autoantibody targets will be required to achieve the performance
characteristics necessary for cancer screening.2 Many informa-
tive cancer-associated antigens have been identiﬁed among
intracellular proteins, including GPR78,3 p53,4 NY-ESO-15 and
CDC25.6 In addition, some cell membrane glycoproteins have
been identiﬁed as potential biomarkers, such as MUC1,7 HER28
and mesothelin.9 The combination of these and other markers
has provided encouraging results, but higher sensitivity and
speciﬁcity are required for screening of the general population.
A key feature of neoplastic cells is alterations in the post-
translational modiﬁcation of proteins and other molecules.10–12
Leading among them are alterations in O-linked glycosylation,
which involves incomplete elongation of O-glycans on surface pro-
teins creating immunogenic epitopes, such as Tn (GalNAc), STn
(NeuAca2,6GalNAc) and T (Galb3GalNAc) antigens.13,14 Highly
glycosylated mucin proteins such as MUC1 and MUC415 are over-
expressed and aberrantly glycosylated in many carcinomas.16,17
The autoantibody response to such MUC1-associated O-glycopep-
tide epitopes has been demonstrated in patients with breast, ovar-
ian, prostate and colorectal cancer.7,18,19 Both IgG autoantibodies
to MUC1 glycoforms and IgA autoantibodies to MUC4 have been
found in colorectal cancer patients.18 Using inhibition studies, epi-
tope mapping and puriﬁcation of autoantibodies with recombinant
proteins, IgA and IgG responses have been shown to be highly
speciﬁc to a combined epitope of an O-glycan and protein back-
bone.18,20 In contrast, IgM antibodies are unsuitable markers of
disease as they recognize all glycoforms of the glycopeptides.19
We now report on the autoantibody signatures to MUC1
and MUC4 glycopeptides in colorectal cancer in both a clini-
cal case–control set and a blinded nested case–control study
with prospective collection of samples before outcome ascer-
tainment.21 The latter sample set from UK Collaborative
Trial of Ovarian Cancer Screening (UKCTOCS) includes
serial samples taken before clinical diagnosis of colorectal
cancer together with serial samples from age-matched con-
trols. The design gave us a unique opportunity to assess
development of an immunological response to aberrantly gly-
cosylated MUC1 and MUC4 over time, and compare it to
our previously reported p53 autoantibody proﬁle in the same
sample set.22 In addition, as the humoral immune response
may have a prognostic impact, we analyzed the association of
autoantibody response before diagnosis and mortality.
Material and Methods
Sample description
Human sera were obtained from two different sources:
Asterand and the UKCTOCS.23
“Time of diagnosis” clinical sample set from Asterand. The
“time of diagnosis” sample set consisted of 157 colorectal
cancer patients (86 males and 71 females; mean age 59.3 6
8.0 years) and 40 controls (20 males and 20 females; mean
age 38.7 6 7.7 years). The sample set included 69 Stage I, 69
Stage II and 19 Stage III patients. Controls were healthy vol-
unteers from the same source. All cancer sera were taken at
the time of diagnosis before cancer treatment, including sur-
gery (further clinical information is provided in Supporting
Information Table 1).
Sample set from the UKCTOCS. Serum samples from indi-
viduals participating in the multimodal arm of UKCTOCS
trial23 were included. In this trial, 50,640 postmenopausal
women were randomized to the multimodal group between
2001 and 2005, and donated samples annually until 2011. A
rigid protocol was followed at all 13 trial centers with regard to
sample collection.22 All women were ﬂagged by the Health and
Social Care Information Centre (HSCIC) for cancers and deaths.
For our study, up-to-date cancer registry data were obtained in
December 2009, yielding a median follow of 6.8 (interquartile
range, IQR 5.9–8.4) years. Colorectal cancer cases were deﬁned
by cancer registration of malignant neoplasm of the colon, recto-
sigmoid junction or rectum (ICD-10 codes C18, C19 and C20)
and a death certiﬁcate where the above ICD-10 codes were pri-
mary or contributory causes of death. Colorectal cancer notiﬁca-
tion was received in 101 women with serial samples, 97 of
whom had given consent for secondary studies. All cancer sera
were collected after randomization to the trial, but before diag-
nosis. Controls were women from the same trial center who had
no history of any cancer at last follow-up and who had donated
serial serum samples during the same period. Controls were
matched to the cancers by age (within 5 years) at sample before
diagnosis in a 1:1 ratio. Three controls were subsequently
excluded from the analysis owing to notiﬁcation of cancer diag-
nosis at ﬁnal follow-up (February 2011). The ﬁnal cohort
What’s new?
Serum antibodies against tumour-associated antigens (TAAs) have shown promise as biomarkers for early cancer detection. In
this study, the authors asked whether autoantibodies to specific glycopeptides correlated with colorectal cancer (CRC). They
found that an assay for autoantibodies to aberrant glycosylated MUC1 predicted CRC with 95% specificity—but with low sensi-
tivity. However, when the assay combined MUC1 with p53, the sensitivity increased to 32%. These finding suggest that a
combination of antibody signatures may eventually enable a biomarker panel for the early detection of CRC.
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consisted of 97 cases (297 samples) and 94 controls (286 serial
samples). Baseline characteristics of the women have been previ-
ously published.22,24 The median age at randomization of
women was 65.0 (25th–75th centiles, 61.3–70.4) for cases and
65.0 (25th–75th centiles, 60.2–69.7) for controls. For our study,
the samples were retrieved from the off-site cryorepository and
allowed to thaw brieﬂy before being aliquoted into 2D barcoded
tubes (0.5-ml Tracker Tubes in Loborack, MP52325, Micronics,
High Wycombe, UK). The tubes were kept at 280C until they
were shipped to the University of Copenhagen where they were
assayed blinded to the case–control status.
Synthetic peptides and recombinant proteins
Synthetic peptides were synthesized at Schaefer-N, Copenhagen,
Denmark. Synthesis of recombinant mucin glycoprotein frag-
ments in Escherichia coli was as follows: N- or C-terminally 63
His- and T7-tagged recombinant fragment of MUC2 and two
MUC4 fragments [short (s) and long (L)] were produced in E.
coli as previously described.18 Gene sequences were inserted into
the bacterial expression vectors pET22 (Novagen), pET28 (Merck
Millipore, Darmstadt, Germany) or pET28 (minus), a modiﬁed
pET 28 vector without N-terminal tags and expressed in Rosetta2
(Novagen), nickel puriﬁed using NiNTA agarose (Qiagen, Venlo,
NL) followed by HPLC puriﬁcation before and after in vitro O-
glycosylation. Products were analyzed by SDS-PAGE and
MALDI-TOF mass spectrometry on a Voyager-DETM PRO
workstation (Applied Biosystems, Life Technologies, Carlsbad,
CA) using 2,5-dihydroxybenzoic acid (Sigma, St. Louis, Missouri)
as matrix.
Microarray
MUC1, MUC2 and MUC4 glycopeptides and glycoproteins were
printed on Schott NexterionVR Slide H MPX 48 (Schott AG,
Mainz, Germany) as previously described.18 In brief, triplicates of
all peptides, in 150 mM sodium phosphate pH 8.5 with 0.005%
CHAPS, were printed on a BioRobotics MicroGrid II spotter
(Genomics Solution) with a 0.21-mm pitch using Stealth 3B
Micro Spotting Pins (Telechem International ArrayIt Division).
After printing, slides were incubated for 1 hr in a humidiﬁed
hybridization chamber with 75% relative humidity and stored
until use at 220C. Before use unspotted slide areas were
blocked for 1 hr with 50 mM ethanolamine in 50 mM sodium
borate, pH 8.5. Human sera were diluted 1:4 and were incubated
in a closed container with gentle agitation for 1 hr, washed thrice
in PBS-Tween, followed by 1-hr incubation with appropriate sec-
ondary antibodies. Human IgG antibodies were detected with
Cy3-conjugated goat anti-human IgG (Fc speciﬁc) (Sigma)
diluted 1:4,000 in PBS-T. Human IgA antibodies were detected
with Cy3-conjugated goat anti-human IgA (Jackson ImmunoRe-
search Laboratories, Inc., West Grove, PA, ). After incubation
with secondary antibodies the slides were washed thrice in PBS-
T, and after the ﬁnal wash, slides were rinsed brieﬂy in H2O,
dried by centrifugation (200g) and scanned in a ProScanArray
HT Microarray Scanner (PerkinElmer) followed by image analy-
sis with ProScanArray Express 4.0 software (PerkinElmer). Each
spot was done in three replicates and the mean value of relative
ﬂuorescence units (RFUs) was used. For comparison, slides were
scanned with identical scanning parameters. The intra-assay
coefﬁcient of variation (CV) of spot triplicates was less than 10%.
Interassay CVs were less than 30% for peptides with RFU values
in the dynamic range.
Statistics
For each peptide, sensitivity was determined at 95% speciﬁcity
for differential diagnosis in the “time of diagnosis” and for
screening in the UKCTOCS sample set. Reactivity was deﬁned as
elevated if above the cutoff deﬁned by the 95th in the control
samples. To investigate if combining the autoantibody informa-
tion to several key peptides improves predictive performance, a
multivariate classiﬁer approach was evaluated. Four different dis-
criminant analysis (DA) methods were assessed (linear, quad-
ratic, logistic and kth nearest neighbor DA) for their
performance characteristics using leave-one-out cross-validation,
where the discriminant function was determined with each sam-
ple left out in turn, and then used to classify that sample. This
helped limit the upward bias in sensitivity resulting from using a
classiﬁcation rule on the same sample it was derived from. Subse-
quently, the predictive ability to identify colorectal cancer cases
was further explored by combining the identiﬁed MUC1 autoan-
tibody data with previously generated autoantibody data to p53
peptide in the same sample set. The p53 set was restricted to the
seven autoantibodies to p53 peptide epitopes (-9, -10, -25, -34, -
43, -44 and -58) that detected autoantibodies in 10% or more of
the cancer patients at a speciﬁcity of 95% in both the “time of
diagnosis” and UKCTOCS samples sets in our previous study.22
A maximum of two peptide autoantibodies from each study was
allowed in the combined classiﬁer to prevent overﬁtting and keep
any biomarker combination clinically feasible. As quadratic DA
had proven to be the best approach, only this method was used
here, and again leave-one-out cross-validation was used.
To investigate whether autoantibodies to MUC1 or MUC4
peptides were prognostic markers related to risk of death
from colorectal cancer, a “competing risks” regression model
was used where the event of interest was death with colo-
rectal cancer as primary or contributory cause, and a death
from any other cause was considered a competing risk. All
models were adjusted for age at sample. Data were analyzed
and plotted using Stata 12 and GraphPad Prism software.
Results
Differential diagnosis using “time of diagnosis” set
IgG autoantibodies to MUC1 glycopeptides. Sensitivity for
detection of colorectal cancer was 16.6% (26=157), 42.0%
(66=157) and 42.0% (66=157) for MUC1-Tn, MUC1-STn
and MUC1-Core3, respectively, at 95% speciﬁcity (Table 1).
Combining MUC1-STn and MUC1-Core3 resulted in a sensi-
tivity of 44.6% (70=157) at 95% speciﬁcity. In keeping with
our previous results, the presence of autoantibodies to
MUC1-STn or MUC1-Core3 was not related to stage (Sup-
porting Information Fig. 1).
E
ar
ly
D
et
ec
ti
on
an
d
D
ia
gn
os
is
2182 Cancer-associated autoantibodies to MUC1 and MUC4
Int. J. Cancer: 134, 2180–2188 (2014) VC 2013 The Authors. Published by Wiley Periodicals, Inc. on behalf of UICC.
Combination of MUC1 and p53. The combination of auto-
antibodies to p53 peptides, p53-43 and p53-58 increased the
predictive ability to MUC1-STn and MUC1-Core3 reactivity.
Autoantibodies to p53-43, MUC1-STn and MUC1-Core3
resulted in the highest sensitivity of 54.8% (86=157) at 95%
speciﬁcity (Table 1).
IgA autoantibodies to MUC4 glycopeptides. Similar to our
previous ﬁndings,18 we found increased IgA reactivity to the
ﬁve short GalNAc-glycosylated MUC4 tandem repeats
(MUC4TR1–5) as well as the two recombinant fragments,
which cover several MUC4 tandem repeats. The sensitivity
varied between 9.6 (15=157) and 22.9% (36=157) at 95% speci-
ﬁcity (Table 2 and Fig. 1). Combination of IgG MUC1 autoan-
tibodies with IgA MUC4 antibodies made little difference to
the performance of the MUC1 autoantibodies alone in the
“time of diagnosis” sample set. Only MUC4TR5Tn appeared
to add to the discriminant power of the MUC1 autoantibodies,
increasing the AUC for the respective ROC curves by 0.046
(p-value for test of equal ROC curves 5 0.031).
Screening using the case–control set from UKCTOCS
In the sample closest to diagnosis (median years before diag-
nosis 0.57 years, IQR 0.25–0.91), the sensitivity for colorectal
cancer at 95% speciﬁcity was 8.2% (8=97) for MUC1-STn
and 13.4% (13=97) for MUC1-Core3 (Fig. 2). Combining
MUC1-STn and MUC1-Core3 reactivity resulted in a sensi-
tivity of 14.4% (14=97) at 95% speciﬁcity (Table 1). No dif-
ference in autoantibody sensitivity for colorectal cancer was
detected in hormone replacement therapy (HRT) versus non-
HRT users. No difference was found for IgA autoantibodies
to nonglycosylated and glycosylated MUC4 peptides between
cases and controls (Table 2 and Fig. 1).
The appearance of autoantibodies to MUC1-STn and MUC1-
Core3 was assessed over time in the serially collected samples
before diagnosis in cases and matched serial samples in controls.
In all MUC1-STn- or MUC1-Core3-positive cancer patients,
detectable autoantibodies were detected in all serial samples taken
before diagnosis (Fig. 3) with a median lead time of 2.23 (IQR
1.69–2.82) and 2.41 years (IQR 1.75–2.72), respectively. Of seven
15-mer p53 peptides from the whole p53 sequence previously
reported,22 autoantibodies to p53-10 and p53-25 showed the
highest added value to the MUC1 glycopeptide responses. On
combining MUC1-STn and MUC1-Core3 autoantibodies with
autoantibodies to these two p53 peptides improved sensitivity
from 14.4 (14=97) to 32.0% (31=97) at 95% speciﬁcity (Table 1).
Prognosis
Of the 97 women with colorectal cancer, 35 died before cen-
sorship on June 13, 2013 (except for two subjects from North-
ern Ireland, censored on August 24, 2012). After correction
for multiple testing, only MUC4TR5 of all the MUC1 or
MUC4 autoantibodies was signiﬁcantly (p 5 0.000011) related
to risk of death in patients with colorectal cancer. An increase
in levels of 1 standard deviation was related to a 12.7% (95%
CI: 6.86%, 18.9%) increase in the subhazard ratio (SHR) for
death from colorectal cancer. In comparison, three (p53-4,
p53-14 and p53-25) of the 18 p53 peptides analyzed were sig-
niﬁcantly (p < 0.05) related to risk of death, with increasing
values associated with increasing risk of CR death (SHR > 1).
Discussion
To our knowledge, this is the ﬁrst study that has investigated
autoantibody responses to aberrantly O-glycosylated MUC1
and MUC4 in prospectively collected sample sets obtained
before clinical diagnosis of colorectal cancer. MUC1-STn and
MUC1-Core3 IgG autoantibodies identiﬁed cases with 8.2
and 13.4% sensitivity, respectively, at 95% speciﬁcity, whereas
IgA to MUC4 glycoforms were unable to discriminate
between cases and controls. Combining MUC1-STn and
MUC1-Core3 reactivity and previously generated p53 peptide
Table 1. IgG autoantibodies to MUC1 glycopeptides and p53 peptides
Peptide
Time of diagnosis CRC
Stage I–III (n 5 157) UKCTOCS cases (n 5 97)
Sensitivity (%) Sensitivity (%)
95% specificity 90% specificity 95% specificity 90% specificity
MUC1 10.2 (16/157) 19.7 (31/157) 7.2 (7/97) 17.5 (17/97)
MUC1-Tn 16.6 (26/157) 35.7 (56/157) 2.1 (2/97) 11.4 (11/97)
MUC1-STn 42.0 (66/157) 50.3 (79/157) 8.2 (8/97) 21.6 (21/97)
MUC1-Core3 42.0 (66/157) 48.4 (76/157) 13.4 (13/97) 23.7 (24/97)
MUC1-Core3 1 MU1-STn 44.6 (70/157) 59.9 (94/157) 14.4 (14/97) 21.6 (21/97)
MUC1-STn 1 p53-10 1 p53-25 20.4 (32/157) 34.4 (54/157) 24.7 (24/97) 32.0 (31/97)
MUC1-Core3 1 p53-10 1 p53-25 35.0 (55/157) 44.0 (69/157) 26.8 (26/97) 41.2 (40/97)
MUC1-Core3 1 MUC1-STn 1 p53-10 1 p53-25 47.8 (75/157) 52.2 (82/157) 32.0 (31/97) 35.1 (34/97)
MUC1-Core3 1 MUC1-STn 1 p53-58 47.8 (75/157) 59.9 (94/157) 19.6 (19/97) 25.8 (25/97)
MUC1-Core3 1 MUC1-STn 1 p53-43 54.8 (86/157) 61.1 (96/157) 23.7 (23/97) 32.0 (31/97)
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reactivity increased sensitivity to 32.0% at 95% speciﬁcity.
These ﬁndings suggest that a combination of antibody signa-
tures may have a role in a panel of early detection markers
for colorectal cancer.
In the context of differential diagnosis, the sensitivity (at
95% speciﬁcity) of the autoantibody response to MUC1-STn
and MUC1-Core3 in the clinical (time of diagnosis) set was
42% for each peptide. Although lower, this was comparable
to our previous ﬁndings (MUC1-STn 56.9%; MUC1-Core3
44.8%) in other clinical sets.18 However, when we assessed
sensitivity (at 95% speciﬁcity) in the context of screening
using the preclinical sample closest to diagnosis in the
population-based UKCTOCS set, it fell to 8.2% for MUC1-
STn and 13.4% for MUC1-Core3 reactivity. Furthermore,
although we found a difference in MUC4 IgA autoantibody
reactivity between patients and controls in the clinical “time
of diagnosis samples” set, there was no difference in the pre-
clinical samples from women from UKCTOCS who devel-
oped colorectal cancer and age-matched controls. The lower
sensitivity in the preclinical sample set is in keeping with
ﬁndings from other studies using the less biased PRoBE (pro-
spective specimen collection before outcome ascertainment
Figure 1. IgA autoantibodies to MUC4 tandem repeat glycopeptides and mucins proteins in “time of diagnosis” and UKCTOCS set. (a) DOT-
PLOT of serum IgA autoantibodies to MUC4 tandem repeat glycopeptides measured by peptide-array assay and expressed as relative fluo-
rescence units (RFUs) (y-axis). (b) DOTPLOT of serum IgA autoantibodies binding to recombinant mucin glycoproteins measured by peptide-
array assay and expressed as RFUs (y-axis). For UKCTOCS set, serum from last sample before diagnosis in colorectal cancer cases (n 5 97)
and last sample taken for controls (n 5 94) were used.
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and retrospective-blinded evaluation) study design21 for evalu-
ating cancer biomarkers for screening.25 It reﬂects both the
fact that the UKCTOCS set is an unbiased population set of
colorectal cancer patients, while all patients who donate sera
for research at time of diagnosis of their cancer are subgroups
of the colorectal patient population and such cohorts are sub-
ject to a host of biases related to their mode of recruitment.
An increased number of controls in UKCTOCS had
MUC1-STn and MUC1-Core3 autoantibodies compared to
the low anti-MUC1 reactivity observed in the “time of diag-
nosis” controls. One explanation for the difference between
the two sample sets is the lack of appropriate matching in
the “time of diagnosis” sample set. Importantly, “time of
diagnosis” control sera were from healthy volunteers with an
average age of 38.7 years, compared with an average age of
59.3 years of cancer patients in the same set. The “time of
diagnosis” controls are therefore likely to have an underre-
presentation of individuals with other medical conditions.26
In addition, the higher average age of the UKCTOCS control
group could have resulted in more individuals with inﬂam-
matory and other noncancer-related medical conditions that
might have contributed to higher levels of MUC1-Core3=STn
reactivity. This is supported by the trend toward higher levels
of autoantibodies to MUC1-Core3 with higher age (Support-
ing Information Fig. 2). In this context, it is noteworthy that
increased levels of autoantibodies to aberrantly glycosylated
MUC1 have been found in patients with gastrointestinal
Table 2. IgA autoantibodies to Tn-MUC1, 2 and 4
Time of diagnosis CRC
Stage I–III (n 5 157)
UKCTOCS
(n 5 97)
Peptide Sensitivity (%)1 Sensitivity (%)1
MUC4TR1 Tn 10.8 (17/157) 7.2 (7/97)
MUC4TR2 Tn 9.6 (15/157) 6.4 (6/97)
MUC4TR3 Tn 17.8 (28/157) 3.1 (3/97)
MUC4TR4 Tn 22.9 (36/157) 2.0 (2/97)
MUC4TR5 Tn 19.7 (31/157) 3.1 (3/97)
recMUC4s Tn 9.6 (15/157) 8.2 (8/97)
recMUC4L Tn 12.1 (19/157) 6.2 (6/97)
MUC1 Tn 19.1 (30/157) 10.3 (10/97)
recMUC2 Tn 17.8 (28/157) 5.2 (5/97)
1At 95% specificity.
Figure 2. IgG autoantibodies to MUC1 glycopeptides in “time of diagnosis” and UKCTOCS set. DOTPLOT of serum IgG autoantibodies bind-
ing to MUC1 glycopeptides measured by peptide-array assay and expressed as relative fluorescence units (RFUs) (y-axis). (a) Serum from
healthy individuals (n 5 40) and colorectal cancer patients (n 5 157) in “time of diagnosis” set. Dotted lines represent 95% specificity.
(b) Serum from last sample before diagnosis in colorectal cancer cases (n 5 97) and last sample taken for controls (n 5 94) from UKCTOCS
set. Dotted lines indicate 90 or 95% specificity.
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inﬂammation.18,27 Another obvious difference between the
two sets is that the “time of diagnosis” set also included male
individuals. However, this is unlikely to have contributed to
the differences, as there was no difference in autoantibody pro-
ﬁle between males and females in the “time of diagnosis” set.
The “time of diagnosis” cases were also not matched to con-
trols for country of residence with a large proportion of the
cancer cases being European Caucasians, while controls were
predominantly American Caucasians. In contrast, the UKC-
TOCS controls were drawn from the same populations as the
cancers and were therefore very closely matched to the cancers
on most baseline characteristics including ethnicity and age.
There is also the possibility that some of the MUC1-Core3
and -STn reactivity in UKCTOCS controls could reﬂect the
presence of occult undiagnosed cancers in the controls. This
would be in accordance with the previously described upregu-
lation of STn in premalignant colonic tissue.28,29 As the UKC-
TOCS cohort is continually being followed up though cancer
registries, it should be possible in due course to address this.
Such issues are common in biomarkers studies using clinical
sets to assess performance characteristics.30
Although a lower percentage of the UKCTOCS cancer
patients were positive for MUC1-Core3 and MUC1-STn com-
pared to the “time of diagnosis” sample set, we did not detect
notable differences between the two sample sets for p53 autoanti-
bodies.22 This indicates that autoantibodies are stable and do not
degrade during the longer intervals to sample processing that in
the UKCTOCS samples. Finally, in the UKCTOCS cohort, HRT
use at recruitment was higher in those who developed colorectal
cancer (p < 0.03). Although HRT has been reported to have con-
founding effects in protein biomarkers studies,31 we found no dif-
ference in autoantibody response to aberrant glycosylated MUC1
between HRT users and non-HRT users.
We previously found that autoantibodies to p53 could
detect 25% of colorectal cancer patients at a median of 1.4
years before clinical diagnosis.22 Combining autoantibodies to
aberrant glycosylated MUC1 and p53 increased the propor-
tion of colorectal cancer cases detected to 32% at 95% speci-
ﬁcity. However, a panel with MUC1 and p53 does not
possess high enough sensitivity as a ﬁrst-line screening test.
Previous studies have shown that a larger antigen panel can
improve sensitivity in clinical sets.8,32–35 Such antigen panels
could be relevant if combined with current screening modal-
ities that include a number of validated tests with high specif-
icities and reasonable sensitivities (e.g., sigmoidoscopy, fecal
occult blood and fecal DNA). Limited compliance is a major
issue in relation to screening using the current tests. Further-
more, colonoscopy as ﬁrst-line screen for colorectal cancer
has recently been questioned given society’s current lack of
capacity for primary colonoscopy screening.36 Incorporation
Figure 3. Autoantibodies in prediagnostic serial samples from colorectal cancer patients (n 5 97) and serial samples from controls (n 5
94) to MUC1 glycopeptides. Each graph represents the autoantibody reactivity to MUC1 glycopeptides. Each symbol represents a single
control or case individual. (a) Number of years to final serum sample taken is indicated for the controls on the x-axis, and (B) number of
years before diagnosis for the cases is indicated on the x-axis. y-Axis represents relative fluorescence units (RFUs).
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of a blood test for autoantibodies in combination with other
biomarkers, such as methylated SEPT9 DNA,37–39 into a “risk
assessment evaluation” test may help to improve compliance
with screening.
Presence of autoantibodies to MUC4TR5, p53-4, p53-14
and p53-25 was signiﬁcantly related to risk of death due to
colorectal cancer, with increasing values associated with
increasing risk. Autoantibodies to p53 have previously been
shown to be associated with decreased survival of patients
with esophageal, colorectal and urological cancers.40–42
In ovarian cancer, however, a large study with 227 patients
showed no correlation,43 whereas other studies have shown
improved survival.44,45 A potential explanation for the sur-
vival beneﬁts described in some studies could be that IgG
immunity to p53 and other tumor antigens reﬂect the pres-
ence of antigen-speciﬁc T cells associated with increased sur-
vival. In contrast to the ﬁndings for p53, it was a surprise
that there was an association between autoantibodies to
MUC4TR5 and risk of death due to colorectal cancer. In this
context, however, it should be noted that MUC4TR5 did not
discriminate between cases and controls and only rather low
levels of reactivity were observed. Further studies are clearly
needed to verify the association between risk of death and
autoantibodies to MUC4TR5. Finally, we found no associa-
tion between risk of death due to colorectal cancer and
MUC1 autoantibodies. Autoantibodies to MUC1 have been
shown to be of prognostic value for poor clinical response
and reduced overall survival in ovarian cancer,46 and other
studies have shown association of autoantibodies to MUC1
to be associated with improved survival in breast cancer,47
gastric cancer,48 pancreatic cancer49 and lung cancer.50
In conclusion, although in clinical samples autoantibodies
to glycosylated MUC1 and MUC4 showed encouraging sensi-
tivity for differential diagnosis of colorectal cancer, their sen-
sitivity for colorectal cancer screening in a population-based
prediagnostic sample set was lower. However, MUC1 autoan-
tibody signatures combined with p53 autoantibody signatures
did detect additional patients than either alone, suggesting
that autoantibody signatures may aid early detection of colo-
rectal cancer. Further validation of these ﬁndings is
warranted.
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